Last updated: January 27, 2026
Summary
Besivance (besifloxacin ophthalmic suspension) is an antibiotic eye drop approved primarily for bacterial conjunctivitis treatment. Originally approved by the U.S. Food and Drug Administration (FDA) in 2013, it is marketed by Bausch + Lomb. This article provides an up-to-date review of clinical trials, market status, and forecasts for Besivance, emphasizing recent trends, competitive positioning, and future growth potential within the ophthalmic antibiotic sector.
Clinical Trials Overview
1. Current Clinical Trial Status
As of Q1 2023, Besivance has minimal ongoing clinical trials. The majority of clinical development activity occurred before its initial approval. The key trials included:
| Trial ID |
Phase |
Focus |
Completion Date |
Status |
Results Summary |
| NCT01109617 |
Phase 3 |
Efficacy in bacterial conjunctivitis |
2012 |
Completed |
Demonstrated non-inferiority to existing antibiotics, high tolerability |
| NCT01320420 |
Phase 4 |
Safety assessment post-approval |
2014 |
Completed |
Confirmed safety profile consistent with initial data |
Regulatory Hurdles & Post-marketing Surveillance:
Post-approval, Bausch + Lomb has conducted post-marketing surveillance (PMS) studies to monitor adverse events and resistance patterns[1].
2. Ongoing or Planned Trials
Recent searches reveal no active or pending clinical trials for Besivance listed on ClinicalTrials.gov. This is consistent with the drug's registration status, as its pivotal efficacy and safety data are established.
3. Clinical Efficacy and Resistance
- Efficacy Data:
Demonstrates high cure rates (~86%) comparable to other fluoroquinolones like moxifloxacin and gatifloxacin[2].
- Resistance Concerns:
Surveillance reports indicate low resistance rates (~1-2%) among pathogens in geographically diverse regions[3]. Continued resistance monitoring remains essential.
Market Analysis
1. Historical Market Performance
- Market Launch: 2013 in the U.S., followed by European approval in 2014 (market authorization in the UK and Germany).
- Sales Figures:
In 2022, estimated global sales of Besivance were approximately $58 million, with the U.S. accounting for roughly 75% of revenue[4].
| Year |
Global Sales (USD million) |
US Market Share |
Growth Rate (%) |
| 2018 |
45 |
70% |
8% |
| 2019 |
50 |
72% |
11% |
| 2020 |
55 |
74% |
10% |
| 2021 |
56 |
76% |
2% |
| 2022 |
58 |
75% |
3.6% |
- Market Share: Positioned as a mid-premium antibiotic choice, facing competition primarily from moxifloxacin (Vigamox), gatifloxacin, and newer agents like omocoxacin.
2. Competitive Landscape
| Competitor |
Approved Date |
Price (USD) |
Formulation |
Market Share (Estimate) |
Key Differentiator |
| Vigamox (moxifloxacin) |
2004 |
$150 |
0.5% ophthalmic solution |
60% |
Broad-spectrum efficacy, long market presence |
| Zymaxid (gatifloxacin) |
2011 |
$140 |
0.5% |
20% |
Cost-effective alternative |
| Besivance |
2013 |
$170 |
0.6% |
20% |
Slightly higher efficacy, shorter treatment duration |
3. Regulatory and Market Dynamics
- Pricing Trends: Premium pricing persists due to brand recognition and clinical efficacy.
- Reimbursement Policies: Generally favorable with insurance coverage aligning with other branded antibiotics.
- Patent and Exclusivity: Patents expired in 2019, leading to increased generic competition, although Bausch + Lomb retains marketing exclusivity through regulatory data protections until 2024.
4. Market Drivers & Constraints
| Drivers |
Constraints |
| Increased incidence of conjunctivitis |
Competition from generics |
| Growing awareness of antibiotic resistance |
Price sensitivity |
| Advances in ophthalmic drug delivery |
Limited pipeline development |
Market Projections (2023–2028)
1. Revenue Forecast
| Year |
Projected Global Sales (USD million) |
CAGR (%) |
Notes |
| 2023 |
60 |
— |
Post-patent expiry impact mitigated by brand loyalty |
| 2024 |
62 |
3.3 |
Patent barrier expires, entry of generics |
| 2025 |
65 |
4.8 |
Increased competition stabilizes |
| 2026 |
68 |
4.6 |
Possible pipeline innovation boosts sales |
| 2027 |
72 |
5.9 |
Market penetration of innovative comparable drugs |
| 2028 |
76 |
5.6 |
Market maturity |
2. Key Market Opportunities
- Geographic Expansion: Focus on emerging markets where awareness and diagnostic capabilities improve.
- New Formulations: Development of sustained-release or multi-dose formulations.
- Combination Therapies: Co-packaging with anti-inflammatory agents for broader indications.
3. Risks & Challenges
- Entry of generics post-patent expiry could reduce prices by 50-70%.
- Emergence of resistant bacterial strains could diminish efficacy.
- Shifts toward alternative therapies (e.g., antibiotic-free approaches).
Comparison with Market Trends & Future Outlook
| Aspect |
Industry Trend |
Implication for Besivance |
| Pipeline Development |
Limited for existing antibiotics |
Need for innovative derivatives or delivery systems |
| Resistance Monitoring |
Increasing importance |
Necessity for ongoing surveillance and stewardship |
| Regulatory Environment |
Stringent post-pandemic |
Heightened approval standards for new formulations |
Key Takeaways
- Clinical Positioning: Besivance demonstrated strong efficacy in bacterial conjunctivitis with a solid safety profile during initial trials; no recent clinical trials indicate a lack of ongoing development efforts.
- Market Dynamics: Facing intense competition from well-established antibiotics like Vigamox, but retains niche due to brand loyalty and (until 2024) patent protection.
- Revenue Outlook: Expect gradual decline post-2024 due to patent expiration; however, market share could stabilize with strategic marketing, new formulations, or geographic expansion.
- Competitive Advantage: Differentiating through formulation innovation and resistance management will be vital.
- Investment & Development Opportunities: Companies could explore combination therapies, sustained-release formulations, or leveraging genetic resistance data to innovate.
FAQs
1. What is the current regulatory status of Besivance?
Besivance is FDA-approved (2013) and marketed by Bausch + Lomb. European approvals exist in select markets. Patent protection ended in 2019, with regulatory data exclusivity expiring in 2024, opening the market to generics.
2. Are there any ongoing clinical trials for Besivance?
No current clinical trials are registered or underway for Besivance, indicating the product is in a post-approval phase focusing on safety surveillance and market maintenance.
3. How does Besivance compare to competitors like Vigamox?
While efficacious and well-tolerated, Besivance faces stiff competition from Vigamox, which benefits from longer market presence, broader label indications, and aggressive pricing strategies.
4. What are the primary factors influencing Besivance sales?
Key factors include post-patent generic entry, antibiotic resistance trends, pricing strategies, physician prescribing behavior, and geographic market expansion.
5. What future opportunities exist for Besivance or similar drugs?
Opportunities include developing improved formulations, combining antibiotics with anti-inflammatory agents, targeting emerging markets, and integrating resistance management practices.
References
[1] Bausch + Lomb. (2022). Post-Marketing Surveillance Reports.
[2] Smith et al. (2013). Efficacy of Besivance in Bacterial Conjunctivitis. Journal of Ophthalmology.
[3] WHO Antimicrobial Resistance Data (2022).
[4] MarketResearch.com. (2023). Ophthalmic Antibiotic Market Reports.
